Longevity, genes,
and disease-modifying AI.

RamanOmics + ML barcode IDs senescent “zombie” cells nondestructively in aging tissue

MIT/MGH multimodal Raman + spatial transcriptomics + ML yields a lipid-linked Raman barcode (≈1131–1135 cm⁻¹) marking p21+ senescent cells in mouse lung/skin — a path toward label-free senescence diagnostics.

Caveat: Mouse tissue / preclinical method paper — not a human diagnostic or therapy; human adaptation and speed still in progress.

First pivotal XLRP gene-therapy trial hits FDA-endorsed LLVA primary (laru-zova / VISTA)

Subretinal RPGR ORF15 gene therapy laruparetigene zovaparvovec: ≥15-letter LLVA improvement at 12 mo in 31% high-dose and 24.1% low-dose vs 0% untreated (n=85 males 12–48); rolling BLA planned; no approved XLRP pharma/GT yet.

Caveat: Company topline — not approved; full peer-reviewed package and regulatory review pending; ocular TEAEs/SAEs (incl. procedure-related) noted in reports.

Salvianolic acids (SAA/SAB/SAE) act as natural senolytics and extend lifespan in aged mice

Danshen-derived phenolic acids selectively kill senescent cells via GSTP1/ROS → apoptosis + ferroptosis; intermittent late-life SAA improved function and lifespan in old mice (authors report ~10.9% median lifespan / large remaining-life effect in advanced-age cohort).

Caveat: Animal data only — not a human longevity indication; no ITP-style multi-lab replication claimed; human use historically short-term PK/safety, not lifespan.

Zanvastro (zilganersen) ASO becomes first FDA-approved disease-modifying therapy for Alexander disease

Intrathecal GFAP-targeted antisense (≈50 mg q3mo) for pediatric and adult Alexander disease — first approved disease-modifying option for this rare leukodystrophy.

Caveat: Rare-disease approval — label/access/price and real-world outcomes still settling; not a general “cure aging/genomics” claim.

In-brain CRISPRi screens map cell-type- and age-specific neuronal genetic vulnerabilities

Scalable cell-type-specific genome-wide CRISPRi in mouse brain finds core essentials plus aging-enriched dependencies (mitochondrial translation, OXPHOS, ribosome biogenesis); overlap with human aging brain downregulation signals.

Caveat: Mouse functional genomics — hypothesis-generating for neurodegeneration targets; not a clinical therapy.

Research AI ≠ clinical cure claims

Preclinical RamanOmics senescence barcodes, company XLRP gene-therapy toplines, mouse senolytic lifespan data, rare-disease ASO approvals, and in-brain CRISPRi screens are different evidence classes. This site keeps them labeled so a headline never collapses into “AI cured aging.”